


## Propranolol hydrochloride

<b>Cat. No.:</b>	HY-B0573
<b>CAS No.:</b>	318-98-9
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>22</sub> ClNO <sub>2</sub>
<b>Molecular Weight:</b>	295.8
<b>Target:</b>	Adrenergic Receptor; Bacterial
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Anti-infection
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



HCl

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : ≥ 150 mg/mL (507.10 mM)					
	H <sub>2</sub> O : 33.33 mg/mL (112.68 mM; Need ultrasonic)					
	* "≥" means soluble, but saturation unknown.					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
<b>1 mM</b>			3.3807 mL	16.9033 mL	33.8066 mL	
<b>5 mM</b>			0.6761 mL	3.3807 mL	6.7613 mL	
	<b>10 mM</b>		0.3381 mL	1.6903 mL	3.3807 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 25 mg/mL (84.52 mM); Clear solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with K <sub>i</sub> values of 1.8 nM and 0.8 nM, respectively <sup>[1]</sup> . Propranolol hydrochloride inhibits [ <sup>3</sup> H]-DHA binding to rat brain membrane preparation with an IC <sub>50</sub> of 12 nM <sup>[2]</sup> . Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy <sup>[3]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	β adrenergic receptor
<b>In Vitro</b>	Propranolol hydrochloride (10 <sup>-7</sup> M-10 <sup>-3</sup> M; 24 and 48 hours) increases the total ERK1/2 levels in a dose-dependent manner, and ERK1/2 activation is observed specifically at 10 <sup>-5</sup> M in HemSCs <sup>[4]</sup> . Propranolol hydrochloride (10 <sup>-9</sup> M-10 <sup>-3</sup> M; 24 and 48 hours) significant decreases cell proliferation at 10 <sup>-4</sup> M propranolol after 24 hours and 10 <sup>-9</sup> M propranolol after 48 hours in HemSCs <sup>[4]</sup> . Propranolol hydrochloride (50 μM-200 μM; 24 hours) increases Annexin V positivity and caspase-3 activation, rapidly induces

HemSC apoptosis<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[4]</sup>

Cell Line:	HemSC cells
Concentration:	10 <sup>-7</sup> M-10 <sup>-3</sup> M
Incubation Time:	24 and 48 hours
Result:	Increased the total ERK1/2 levels in a dose-dependent manner.

Cell Viability Assay<sup>[4]</sup>

Cell Line:	HemSC cells
Concentration:	10 <sup>-9</sup> M-10 <sup>-3</sup> M
Incubation Time:	24 and 48 hours
Result:	Suppressed HemSC Proliferation.

Apoptosis Analysis<sup>[4]</sup>

Cell Line:	HemSC cells
Concentration:	50 μM, 100 μM, or 200 μM
Incubation Time:	24 hours
Result:	Induced HemSC cell death occurred via an apoptotic pathway.

#### In Vivo

Propranolol hydrochloride (orally administration; 40 mg/kg; daily) significantly reduces the vessel diameter relative to the vehicle-treated implants, and increases the number of cells that expressed phosphorylated ERK1/2 within the IH Matrigel implant<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	A xenograft mouse model of IH (infantile hemangiomas) with HemSC cells <sup>[4]</sup>
Dosage:	40 mg/kg
Administration:	Orally administration; 40 mg/kg; daily
Result:	Improved vessel development in the IH mouse model that correlated with MAPK pathway activation.

#### CUSTOMER VALIDATION

- Nat Commun. 2023 May 2;14(1):2523.
- Chemosphere. 2019 Jun;225:378-387.
- Sci Signal. 2020 Nov 24;13(659):eaax0273.
- Am J Pathol. 2023 Apr 21;S0002-9440(23)00132-3.
- iScience. 2023 Jul 19.

---

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Galandrin S, et al. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. *Mol Pharmacol*. 2006 Nov;70(5):1575-84. Epub 2006 Aug 1
- [2]. Briley M, et al. Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties. *Br J Pharmacol*. 1980 Aug;69(4):669-73.
- [3]. Al-Majed AA, et al. Propranolol. *Profiles Drug Subst Excip Relat Methodol*. 2017;42:287-338.
- [4]. Munabi NC, et al. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. *Stem Cells Transl Med*. 2016 Jan;5(1):45-55.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA